Pfizer Total Long Term Liabilities 2010-2024 | PFE

Pfizer total long term liabilities from 2010 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
  • Pfizer total long term liabilities for the quarter ending September 30, 2024 were $84.400B, a 2.12% decline year-over-year.
  • Pfizer total long term liabilities for 2023 were $89.418B, a 51.17% increase from 2022.
  • Pfizer total long term liabilities for 2022 were $59.149B, a 3.58% decline from 2021.
  • Pfizer total long term liabilities for 2021 were $61.342B, a 5.39% decline from 2020.
Pfizer Annual Total Long Term Liabilities
(Millions of US $)
2023 $89,418
2022 $59,149
2021 $61,342
2020 $64,836
2019 $66,844
2018 $63,806
2017 $69,714
2016 $80,660
2015 $72,985
2014 $74,358
2013 $72,115
2012 $74,934
2011 $76,472
2010 $78,113
2009 $85,278
Pfizer Quarterly Total Long Term Liabilities
(Millions of US $)
2024-06-30 $84,400
2024-03-31 $88,039
2023-12-31 $89,418
2023-09-30 $86,680
2023-06-30 $86,227
2023-03-31 $57,819
2022-12-31 $59,149
2022-09-30 $58,145
2022-06-30 $60,410
2022-03-31 $61,887
2021-12-31 $61,342
2021-09-30 $61,418
2021-06-30 $63,941
2021-03-31 $63,299
2020-12-31 $64,836
2020-09-30 $79,335
2020-06-30 $80,648
2020-03-31 $67,108
2019-12-31 $66,844
2019-09-30 $68,077
2019-06-30 $64,244
2019-03-31 $66,839
2018-12-31 $63,806
2018-09-30 $67,161
2018-06-30 $62,701
2018-03-31 $66,706
2017-12-31 $69,714
2017-09-30 $82,824
2017-06-30 $82,682
2017-03-31 $85,174
2016-12-31 $80,660
2016-09-30 $80,070
2016-06-30 $75,492
2016-03-31 $70,848
2015-12-31 $72,985
2015-09-30 $75,897
2015-06-30 $69,555
2015-03-31 $72,832
2014-12-31 $74,358
2014-09-30 $73,137
2014-06-30 $73,718
2014-03-31 $68,950
2013-12-31 $72,115
2013-09-30 $76,794
2013-06-30 $76,908
2013-03-31 $77,028
2012-12-31 $74,934
2012-09-30 $71,357
2012-06-30 $72,083
2012-03-31 $74,912
2011-12-31 $76,472
2011-09-30 $77,746
2011-06-30 $76,465
2011-03-31 $75,252
2010-12-31 $78,113
2010-09-30 $79,175
2010-06-30 $79,512
2010-03-31 $79,107
2009-12-31 $85,278
2009-09-30 $51,052
2009-06-30 $49,995
2009-03-31 $39,151
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $151.422B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51